At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Metyrapone Capsulesdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism
In Brief
An observational study evaluating Metyrapone Capsules for Hypercortisolism. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypercortisolism
CountriesItaly
CollaboratorsHRA Pharma
Timeline
N/ACompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionJun 2025
Study CompletionDec 2025
TodayJul 2026
First PostedFeb 25, 2022
Enrollment StartApr 28, 2022
Primary CompletionJun 30, 2025
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 4.4 years ago
Interventions
Metyrapone Capsulesdrug
Exposure to 24 weeks of treatment with metyrapone